Dr Reddy's Laboratories is expected to report a slight increase in revenue and 12% growth in net profit for Q3. The blockbuster cancer drug Revlimid will continue to contribute significantly to the US revenue, but lower sales of other drugs and weak domestic market performance may affect overall growth. Margins are expected to remain stable due to the sustained contribution from Revlimid.